

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.
You can purchase shares of MeiraGTx Holdings (NASDAQ:MGTX) through any online brokerage.
Other companies in MeiraGTx Holdings’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MeiraGTx Holdings has a consensus price target of $22.67.
The stock price for MeiraGTx Holdings (NASDAQ: MGTX) is $9.32 last updated November 2, 2026 at 4:00 PM EST.
There are no upcoming dividends for MeiraGTx Holdings.
MeiraGTx Holdings does not have any upcoming earnings scheduled.
There is no upcoming split for MeiraGTx Holdings.
MeiraGTx Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated...